The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy
Jiayi Liu,Wei Li,Ke-Qiong Deng,Song Tian,Hui Liu,Hongjie Shi,Qian Fang,Zhen Liu,Ze Chen,Tian Tian,Shanyu Gan,Fengjiao Hu,Manli Hu,Jiayi Liu,Wei Li,Ke-Qiong Deng,Song Tian,Hui Liu,Hongjie Shi,Qian Fang,Zhen Liu,Ze Chen,Tian Tian,Shanyu Gan,Fengjiao Hu,Manli Hu,Xu Cheng,Yan-Xiao Ji,Peng Zhang,Zhi-Gang She,Xiao-Jing Zhang,Shaoze Chen,Jingjing Cai,Hongliang Li
DOI: https://doi.org/10.1161/circresaha.121.318866
IF: 23.213
2022-04-19
Circulation Research
Abstract:Background: Pathological cardiac hypertrophy is one of the leading causes of heart failure with highly complicated pathogeneses. The E3 ligase TRIM16 (tripartite motif–containing protein 16) has been recognized as a pivotal regulator to control cell survival, immune response, and oxidative stress. However, the role of Trim16 in cardiac hypertrophy is unknown. Methods: We generated cardiac-specific knockout mice and adeno-associated virus serotype 9–Trim16 mice to evaluate the function of Trim16 in pathological myocardial hypertrophy. The direct effect of TRIM16 on cardiomyocyte enlargement was examined using an adenovirus system. Furthermore, we combined RNA-sequencing and interactome analysis that was followed by multiple molecular biological methodologies to identify the direct target and corresponding molecular events contributing to TRIM16 function. Results: We found an intimate correlation of Trim16 expression with hypertrophy-related heart failure in both human and mouse. Our functional investigations and unbiased transcriptomic analyses clearly demonstrated that Trim16 deficiency markedly exacerbated cardiomyocyte enlargement in vitro and in transverse aortic constriction–induced cardiac hypertrophy mouse model, whereas Trim16 overexpression attenuated cardiac hypertrophy and remodeling. Mechanistically, Prdx1 (peroxiredoxin 1) is an essential target of Trim16 in cardiac hypertrophy. We found that Trim16 interacts with Prdx1 and inhibits its phosphorylation, leading to a robust enhancement of its downstream Nrf2 (nuclear factor–erythroid 2–related factor 2) pathway to block cardiac hypertrophy. Trim16-blocked Prdx1 phosphorylation was largely dependent on a direct interaction between Trim16 and Src and the resultant Src ubiquitinational degradation. Notably, Prdx1 knockdown largely abolished the anti-hypertrophic effects of Trim16 overexpression. Conclusions: Our findings provide the first evidence supporting Trim16 as a novel suppressor of pathological cardiac hypertrophy and indicate that targeting the Trim16-Prdx1 axis represents a promising therapeutic strategy for hypertrophy-related heart failure.
cardiac & cardiovascular systems,peripheral vascular disease,hematology